NRXP: FDA Approves Expanded Access

NRx Pharma Announces FDA Approval Of Intermediate Population Expanded Access Protocol For Use Of NRX-101, Fixed Dose Combination Of DCS And Lurasidone For Augmentation Of Accelerated TMS